Objection: Marketing authorisation for Paxlovid

This procedure concerns an objection to granting marketing authorisation for the medicinal product Paxlovid, containing Nirmatrelvir and ritonavir. It is a regulatory procedure based on specific parliamentary rules.

This objection affects the approval process for a new human medicine. It allows Parliament to scrutinize and potentially block the European Commission's implementing act for authorisation.